. 2016 Mar 16;7(24):35803–35812. doi: 10.18632/oncotarget.8130

Table 3. Overall survival according to TKI position (3rd-line vs 2nd-line) and overall sequence (CT-CT-TKI vs CT-TKI-CT).

	Treatment	mOS (months)	N	HR	95% CI	P
TKI position	3rd-line TKI	26	22	0,68	0,42 – 1,09	0,11
TKI position	2nd-line TKI	15	51	0,68	0,42 – 1,09	0,11
Overall sequence	CT-CT-TKI	26	21	0,70	0,39 – 1,24	0,21
Overall sequence	CT-TKI-CT	18	26	0,70	0,39 – 1,24	0,21